Qualigen Therapeutics, Inc. (NASDAQ:QLGN) Short Interest Update

Qualigen Therapeutics, Inc. (NASDAQ:QLGN) was the recipient of a large growth in short interest during the month of November. As of November 15th, there was short interest totalling 94,400 shares, a growth of 505.1% from the October 31st total of 15,600 shares. Currently, 14.1% of the company’s shares are short sold. Based on an average daily volume of 82,400 shares, the days-to-cover ratio is presently 1.1 days.

Qualigen Therapeutics Stock Performance

Qualigen Therapeutics stock traded down $0.04 during trading hours on Friday, reaching $4.62. 17,126 shares of the company’s stock traded hands, compared to its average volume of 93,696. Qualigen Therapeutics has a fifty-two week low of $3.34 and a fifty-two week high of $37.45. The firm’s 50 day moving average is $6.36 and its 200-day moving average is $9.48.

About Qualigen Therapeutics

Qualigen Therapeutics, Inc, a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints.